Therapeutic genome editing harnesses the power of genome editing tools to correct erroneous genes associated with disease pathology. To bring the...
Read More »EXOSOME NEWS
Immuno-acoustic sorting of disease-specific extracellular vesicles by acoustophoretic force
Methods for the isolation and analysis of extracellular vesicles (EVs) have been extensively explored in the field of life science and in clinical...
Read More »Current landscape of tumor-derived exosomal ncRNAs in glioma progression, detection, and drug resistance
Glioma is the most common and fatal tumor of the central nervous system in humans. Despite advances in surgery, radiotherapy, and chemotherapeutic agents, glioma still has a poor prognosis. The ...
Read More »Exosome-based rare earth nanoparticles for targeted in situ and metastatic tumor imaging with chemo-assisted immunotherapy
In this research, a tumor exosome system DOX/2DG@E-RENPs with good biocompatibility, low immunogenicity, and high targeting effect was proposed for theranostics with high chemo-/starvation/immunotherapy efficiency. DOX and 2-deoxy-D-glucose (DOX/2DG) together ...
Read More »Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers
Exosomes are extracellular vesicles with a diameter of 30-150 nm that function in mediating intercellular communication and intercellular material exchange. The liposomal membrane of exosomes protects the...
Read More »Innocan announces the execution of a research & license agreement with Ramot, the technology transfer company of the Tel Aviv University for cannabinoids loaded exosome delivery platform (clx)
Innocan Pharma Corporation, is pleased to announce today that after the early substantial positive results of its CBD Loaded Exosome Platform (CLX), its Company’s wholly-owned subsidiary, InnoCan Pharma Ltd...
Read More »First point of attack: Understanding the entry mechanism of SARS-CoV-2 into human cells
The biology of SARS-CoV-2, the virus behind the COVID-19 pandemic, remains partially elusive. Understanding viral mechanisms is a key factor in developing effective treatment strategies against...
Read More »Advances in biosensors technology for detection and characterization of extracellular vesicles
Exosomes are extracellular vehicles (EVs) that encapsulate genomic and proteomic material from the cell of origin that can be used as biomarkers...
Read More »Cystic Fibrosis Foundation awards $766,000 to Carmine Inc to test use of extracellular vesicles in its non-viral gene therapy program
The Cystic Fibrosis Foundation announced today that it has awarded more than $1.8 million to three companies for early-stage research into potential genetic therapies for cystic fibrosis as part of ...
Read More »Jobs
-
Featured Exosome Job – Scientist, Regenerative Medicine – Exosomes
Contribute to our expanding range of translational preventive and regenerative medicine work with exosomes from different source cells, including iPSCs and many iPSC-derived cell types like MSCs, HSCs,...
Read More » -
Post-doc position available – Clinical and Translational Research
-
Featured Exosome Job – Research Associate II, Exosome Engineering, Protein Sciences
-
Postdoc position available – microchip-based exosome sensors
-
Post-doc position available – new pathways in endosome formation and extracellular vesicle secretion in metastasis
Industry News
-
Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
Coya Therapeutics announced the execution of an option agreement for exclusive worldwide rights to a novel and proprietary technology platform enabling...
Read More » -
Exosome Engineering Strategies for Cargo Loading and Targeting Delivery
-
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Treg-Derived Exosome Therapeutics
-
Novel assay for early detection of ovarian cancer in extracellular vesicles significantly outperforms current standard test
-
Evox Therapeutics Presents Progress Across its DeliverEX™ Exosome Therapeutics Platform